FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
Name and Address of Reporting Person* Amado Rafael				2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)Director10% Owner						
(Last) (First) (Middle) THE RESIDENCES AT TWO LIBERTY PLACE,, 50 S 16TH STREET APT #4805				3. Date of Earliest Transaction (Month/Day/Year) 08/06/2019								X Officer (give title below) Other (specify below) President, R&D						
PHILAD	ELPHIA,	(Street) PA 19102		4. If A	Amendn	nent,	Date	Origin	nal Fil	ed(Month	/Day/Year	r)		X_Form file	ed by One Repo	Group Filing orting Person One Reporting	• • •	ble Line)
(City	')	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	Exect		tion Date, if	(Instr. 8)		(A) or Disposed of		d of ((D) Benefici Reported		ant of Securities ally Owned Following d Transaction(s)		6. Ownership Form:	Beneficial		
				(Month/Day/Year)			ode	V	Amoun	(A) or (D)	Pri	ice	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
American Depositary Shares representing Ordinary Shares 08/06/2019		08/06/2019				S		11,04	3 D	\$ 2.0 (2))6	17,237 ⁽³⁾			D			
Reminder.	Report on a	separate fine re	r each class of secur	Deriva	tive Sec	curit	ies Ac	l t cquire	Personta conta the fo	ons whained in	o responding this for this for Bo	orm a a cur enefic	are rrent	not requ tly valid		ormation spond unle rol numbe	ss	1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	*****	3A. Deemed Execution Da	te, if 4. Trans Code	4. Transact Code	e cr. 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7 A U S	7. Tit Amou Jnder Secur Instr	le and unt of rlying rities . 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Security Direct (or Indir	Ownersh (Instr. 4)
					Code	V	(A)	(D)	Date Exerc		Expirati Date	ion T	Γitle	Amount or Number of Shares				

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Amado Rafael THE RESIDENCES AT TWO LIBERTY PLACE, 50 S 16TH STREET APT #4805 PHILADELPHIA, PA 19102			President, R&D				

Signatures

/s/ Rafael Amado	08/07/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 6, 2018 and which vested on August 6, 2019. Once
- (1) vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from \$2.02 to \$2.085, inclusive. Upon request, (2) the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.
- The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on (3) this Form 4. Additionally, the Reporting Person holds 20,974 ADSs and RSU-style options and other options covering an aggregate of 9,356,928 ordinary shares of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.